Testing of New Therapeutic Agents in Human Primary Cells v1

  • Research type

    Research Study

  • Full title

    In vitro assay systems involving the use of human primary cells such as hepatocytes, hepatic stellate cells, whole blood and cells isolated from whole blood for testing potential new therapeutic agents.

  • IRAS ID

    275491

  • Contact name

    Nicola Crawford

  • Contact email

    nicola.crawford@crl.com

  • Sponsor organisation

    Charles River Discovery Ltd

  • Duration of Study in the UK

    5 years, 0 months, 0 days

  • Research summary

    The ability to test compounds in assays that involve human tissue is critical in any programme designed to develop new therapeutic entities for human application. Although many test systems involve the use of animal cells, organs or living animals certain critical data can only be obtained from experiments using human tissue. Hepatocytes, hepatic stellate cells, whole blood and cells derived from whole blood are probably the most widely used human tissues chosen for such studies. Fresh and frozen cells and blood is readily obtainable from commercial sources. Work will be performed to test new therapeutic agents on behalf of other commercial or academic organisations requiring the evaluation of substances that may have potential for treatment of disease areas such as oncology and respiratory or other systems. Primary human cells (for example hepatocytes, whole blood cells and cells isolated from whole blood) will be used to evaluate the potency of test substances at inhibiting or activating functional activity or for adverse effects on these cells.

  • REC name

    Yorkshire & The Humber - Sheffield Research Ethics Committee

  • REC reference

    20/YH/0191

  • Date of REC Opinion

    17 Jun 2020

  • REC opinion

    Favourable Opinion